Press release content from Business Wire. The AP news staff was not involved in its creation.
Turn Therapeutics Receives Authorization to Commence Human Trial for COVID-19 Therapeutic Candidate
January 21, 2021 GMT
LOS ANGELES (BUSINESS WIRE) Jan 21, 2021
Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the initiation of a two-part, four-arm, human safety and efficacy trial for its flagship product, Hexagen, to be used in the fight against COVID-19. This randomized, placebo-controlled trial will enroll approximately 100 mild to moderate COVID-19 patients and 50 healthcare workers across four leading hospitals in Panama, including internationally recognized Gorgas Memorial Institute of Health Studies ( GMH ), which will also serve as the central laboratory for sample analysis.